December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Absci Corporation - Common Stock (NQ:ABSI)

9.660 +0.480 (+5.23%)
Delayed Quote Updated: 2:26 PM EDT, Oct 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Absci Corporation - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Absci Appoints Zach Jonasson, Ph.D., as Chief Financial Officer and Chief Business Officer
Addition of veteran biotech leader to further support Absci’s next stage of growth 
From Absci Corporation
Via GlobeNewswire
News headline image
Absci and Caltech Join Forces, Bolstered by Major Grant, to Accelerate Affordable HIV Therapeutic Vaccine Development
From Absci Corporation
Via GlobeNewswire
News headline image
Absci to Participate in the UBS MedTech, Tools and Genomics Summit 2023
From Absci Corporation
Via GlobeNewswire
News headline image
Absci's Return On Capital Employed Insights ↗
 
Via Benzinga
Absci Earnings Perspective: Return On Capital Employed ↗
 
Via Benzinga
News headline image
Absci to Participate in the Canaccord Genuity 43rd Annual Growth Conference
From Absci Corporation
Via GlobeNewswire
News headline image
Absci to Participate in the Morgan Stanley 2nd Annual Biotechnology AI Summit
From Absci Corporation
Via GlobeNewswire
News headline image
Absci Evolves its Board of Directors with HealthTech Luminary Frans van Houten, Former CEO of Philips
From Absci Corporation
Via GlobeNewswire
News headline image
Absci Reports Business Updates and First Quarter 2023 Financial and Operating Results
From Absci Corporation
Via GlobeNewswire
News headline image
Why ZIM Integrated Shipping Services Shares Are Trading Lower By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers Greenhill & Co., Inc. (NYSE: GHL) shares jumped 116.4% to $14.67 after Mizuho announced it would acquire the company for $15 per share. 
Via Benzinga
News headline image
University of Oxford’s Kennedy Institute of Rheumatology Partners with Absci to Accelerate AI-Driven Immunotherapies
Absci will apply its generative AI platform to The Kennedy Institute’s immunology biorepository to speed the discovery and development of multiple therapies 
From Absci Corporation
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2023 ↗
 
Via Benzinga
News headline image
Absci to Participate in the 22nd Annual Needham Virtual Healthcare Conference
From Absci Corporation
Via GlobeNewswire
News headline image
Absci Partners with Bioinformatics Company M2GEN to Accelerate Drug Creation for Oncology
Absci’s generative AI platform will use M2GEN’s industry-leading clinicogenomic database with the aim of creating better cancer treatments faster 
From Absci Corporation
Via GlobeNewswire
News headline image
Absci Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
From Absci Corporation
Via GlobeNewswire
News headline image
Absci to Participate in the B. Riley Securities' Life Sciences Tools Conference - Proteomics Setting the Blueprint for Innovative Drug Creation
From Absci Corporation
Via GlobeNewswire
News headline image
Absci to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
From Absci Corporation
Via GlobeNewswire
News headline image
Absci Expands in Europe with Launch of New Innovation Center and Additional Senior Leadership in Switzerland
The generative AI drug company ramps up its internal pipeline and R&D portfolio, tapping into European markets, talent, and tech 
From Absci Corporation
Via GlobeNewswire
News headline image
Absci to Participate in the 43rd Annual Cowen Health Care Conference
From Absci Corporation
Via GlobeNewswire
News headline image
St. John’s Cancer Institute Partners with Absci to Expedite Development of Cancer Therapies
From Absci Corporation
Via GlobeNewswire
News headline image
Absci Deepens Scientific Advisory Board to Accelerate Generative AI Drug Creation
In silico antibody design expert Dr. Victor Greiff, synthetic biology pioneer Dr. Timothy Lu, and translational medicine veteran Dr. Hubert Truebel will strengthen Absci’s scientific leadership in... 
From Absci Corporation
Via GlobeNewswire
News headline image
Absci First to Create and Validate De Novo Antibodies with Zero-Shot Generative AI
From Absci Corporation
Via GlobeNewswire
News headline image
Absci to Participate in the 41st Annual J.P. Morgan Healthcare Conference
From Absci Corporation
Via GlobeNewswire
News headline image
Absci to Participate in the 41st Annual J.P. Morgan Healthcare Conference
From Absci Corporation
Via GlobeNewswire
News headline image
Absci to Participate in the Berenberg Discover AI Seminar
From Absci Corporation
Via GlobeNewswire
News headline image
Absci to Participate in the Piper Sandler Healthcare Conference
From Absci Corporation
Via GlobeNewswire
News headline image
Absci Reports Third Quarter 2022 Financial Results
From Absci Corporation
Via GlobeNewswire
News headline image
Absci to Participate in the Stifel Healthcare Conference
From Absci Corporation
Via GlobeNewswire
News headline image
Absci Welcomes Meta Senior Executive to Board of Directors
Technology veteran Dan Rabinovitsj provides expertise in collaborating with technology partners to catalyze innovation as Absci accelerates generative AI drug creation 
From Absci Corporation
Via GlobeNewswire
News headline image
Absci to Participate in the 31st Annual Credit Suisse Healthcare Conference
From Absci Corporation
Via GlobeNewswire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.